ProQR R&D day

ProQR organized its second R&D Day on June 15, 2017 in New York, NY.

The R&D Day featured presentations by ProQR management on the progress on its pipeline, including a review and introduction of several near- and medium term value drivers. In addition, several key opinion leaders discussed the state of the art in research and development on critical areas of the company’s pipeline including CF, inherited blindness, debilitating skin diseases and RNA technologies.

Webcast & Slides
Please use one of the buttons below to watch a replay of the webcast or download the presentation. In order to watch the webcast you need to register first.

Summary of discussed topics during R&D Day
  • Presentations on development programs: QR-010 for cystic fibrosis, QR-110 for Leber’s congenital amaurosis Type 10 (LCA 10) and QR-313 for dystrophic epidermolysis bullosa (DEB)
  • An update on the Ophthalmology pipeline including programs for Usher syndrome and the Dermatorlogy pipeline including other DEB mutations
  • An introduction to ProQR’s novel RNA editing platform technology called Axiomer
Program / timetable
ProQR speakers
  • Daniel de Boer - Chief Executive Officer
  • Noreen Henig, M.D. - Chief Medical Officer
  • Peter Adamson, Ph.D. - Head of Ophthalmology Research
  • Gerard Platenburg - Chief Innovation Officer
  • Dave Rodman - Chief Development Strategy Officer
Key Opinion Leader speakers
  • Stephen Rose, Ph.D. - Chief Research Officer at Foundation Fighting Blindness
  • Art Levin, Ph.D. - Executive Vice President, Research and Development at Avidity Biosciences
  • Steven M. Rowe, M.D., MSPH. - Professor, Department of Medicine, Pediatrics and Cell Developmental & Integrative Biology; Director, Gregory Fleming James Cystic Fibrosis Research Center University of Alabama
  • M. Peter Marinkovich, M.D. - Associate Professor, Blistering Disease Clinic Department of Dermatology at Stanford University School of Medicine

You are now leaving ProQR Therapeutics

ProQR Therapeutics provides links to web sites of other organizations in order to provide visitors with certain information. A link does not constitute an endorsement of content, viewpoint, policies, products or services of that web site. Once you link to another web site not maintained by ProQR Therapeutics, you are subject to the terms and conditions of that web site, including but not limited to its privacy policy.

You will be redirected to

Click the link above to continue or CANCEL